Quarterly ResultMay 7, 2026, 04:20 PM
4DMT Q1 Net Loss $68.8M; 4D-150 4FRONT-1 Enrollment Complete
AI Summary
4D Molecular Therapeutics reported a net loss of $68.8 million for Q1 2026, compared to $48.0 million in Q1 2025, with R&D expenses increasing to $65.0 million due to Phase 3 trials. The company announced significant operational progress, including the completion of enrollment and randomization for its 4D-150 4FRONT-1 wet AMD Phase 3 trial, with topline data expected in H1 2027. Cash, cash equivalents, and marketable securities stood at $458 million, projected to fund operations into the second half of 2028.
Key Highlights
- 4D-150 4FRONT-1 wet AMD Phase 3 trial enrollment (N=523) completed in March 2026.
- Q1 2026 net loss was $68.8 million, compared to $48.0 million in Q1 2025.
- Q1 2026 R&D expenses increased to $65.0 million from $40.7 million year-over-year.
- Cash, cash equivalents, and marketable securities totaled $458 million as of March 31, 2026.
- Cash position expected to fund current operating plan into the second half of 2028.
- 4D-150 4FRONT-2 enrollment completion expected H2 2026; topline data H2 2027.
- 4D-150 PRISM wet AMD Phase 2b 2-year data expected in Q3 2026.
- Global Phase 3 trial for 4D-150 in DME expected to initiate in Q3 2026.